NCT06603597招募中不适用
Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 12
- 主要终点
- Overall survival rate
研究概览
简要总结
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage I-IV HER2-positive breast cancer
排除标准
- 未提供
结局指标
主要结局
Overall survival rate
时间窗: From diagnosis to 5 years after diagnosis
For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.
次要结局
- Pathologic complete response rate(From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment)
研究者
Priyanka Sharma
Professor of Medicine
University of Kansas Medical Center
研究点 (12)
Loading locations...
相似试验
已完成
不适用
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 YearsBreast CancerNCT01480674Hoffmann-La Roche160
已完成
不适用
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin TherapyBreast CancerNCT01777958Hoffmann-La Roche135
已完成
不适用
HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyUrothelial CarcinomaNCT05902494Seagen, a wholly owned subsidiary of Pfizer389
已完成
不适用
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a TaxaneMetastasesBreast CancerNCT00097487Genentech, Inc.1,000
Unknown
2 期
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneHER2-positive Breast CancerBrain MetastasesNCT04158947xuexin he130